Application of fatty acid and lipid measurements in neuropsychiatry

Clinical Chemistry and Laboratory Medicine : CCLM
Agatha GrelaWojciech Piekoszewski

Abstract

The importance of lipids in the understanding of disease states is constantly increasing. Whilst the link between metabolic disorders and lipids seems to be clear, interpreting lipid regulation in the context of neuropsychiatric disorders is a new approach. Mental disorders account for almost 15% of the total global disease burden with Alzheimer's disease, depression or schizophrenia being amongst the most widespread mental disorders in the general population. For this reason rapid and early diagnosis is crucial and finding the right biomarkers is of great importance. Lipids appear to be essential in learning the aetiopathology of neuropsychiatric diseases as well as in biomarker research as they are most abundantly present in the brain. This study discusses recent findings in neuropsychiatry in the context of lipid analysis.

References

Apr 30, 1977·Lancet·D F Horrobin
Mar 21, 1992·Lancet·H Engelberg
Jul 1, 1985·The Proceedings of the Nutrition Society·A D SmithJ Belin
Oct 1, 1995·The American Journal of Clinical Nutrition·L J StevensJ R Burgess
Sep 27, 1993·Archives of Internal Medicine·B S McEwen, E Stellar
Jan 27, 1996·BMJ : British Medical Journal·P H SteegmansD E Grobbee
Aug 30, 2000·Psychiatry Research·J C AlvarezO Spreux-Varoquaux
Jan 22, 2001·The Journal of Biological Chemistry·B MirnikjooE J Weeber
Oct 29, 2003·Chemistry and Physics of Lipids·William Stillwell, Stephen R Wassall
Mar 12, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·George I PapakostasMaurizio Fava
Mar 18, 2004·International Journal of Geriatric Psychiatry·U G O ErgünE Akpinar
Dec 2, 2004·The Tohoku Journal of Experimental Medicine·Mutsuhiro Nakao, Eiji Yano
Oct 25, 2006·Journal of Studies on Alcohol·Katie O'DonnellAndrew Steptoe
Dec 21, 2006·Archives of Suicide Research : Official Journal of the International Academy for Suicide Research·Dan RujescuIna Giegling
Feb 10, 2007·Psychiatry Research·William Coryell, Michael Schlesser
Apr 19, 2007·Molecular Psychiatry·R Kaddurah-DaoukK R R Krishnan
Jul 27, 2007·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Rainald MössnerPeter Riederer
Aug 23, 2007·Journal of Geriatric Psychiatry and Neurology·Nikolaos DimopoulosAnastasios Kalofoutis
Sep 20, 2007·Lipids in Health and Disease·Brian M RossLee E Sieswerda
Nov 3, 2007·International Journal of Geriatric Psychiatry·Sinikka BotsAulikki Nissinen
Feb 19, 2008·Current Opinion in Psychiatry·Catherine OwenGordon Parker
Jun 3, 2008·Electrophoresis·Emanuel Schwarz, Sabine Bahn
Jun 28, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Soili M LehtoHeimo Viinamäki
Sep 9, 2008·The Australian and New Zealand Journal of Psychiatry·Michael BerkJulie A Pasco
Sep 13, 2008·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·Ju Young ShinRené Martin
Mar 28, 2009·Anxiety, Stress, and Coping·Maria Balle, Miquel Tortella-Feliu
Jul 25, 2009·Antioxidants & Redox Signaling·Rao Muralikrishna Adibhatla, James Franklin Hatcher
Aug 14, 2009·Nutrition Reviews·Elizabeth R Bertone-Johnson

❮ Previous
Next ❯

Citations

May 20, 2020·Translational Psychiatry·María Alemany-NavarroPino Alonso
Jun 3, 2021·Food & Function·Haining YuWeiguang Shan

❮ Previous
Next ❯

Methods Mentioned

BETA
NMR
transgenic

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.